Deprecated: Return type of Twig\Markup::count() should either be compatible with Countable::count(): int, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /www/scri2022_179/public/wp-content/plugins/timber-library/vendor/twig/twig/src/Markup.php on line 38
Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.
Tinhofer, I, Marschitz, I, Kos, M, Henn, T, Egle, A, Villunger, A, Greil, R BLOOD. 1998, 92(10): 271B-271B.
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, ZГ¶chbauer-MГјller S, Huber H, Pirker R. Eur J Cancer. 1998 Nov,34(12):1977-80.
View this publication in the PUBMED databaseInterferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J. Leuk Res. 1998 Oct,22(10):881-6.
View this publication in the PUBMED databaseLeg ulcers associated with long-term hydroxyurea therapy.
Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. J Am Acad Dermatol. 1998 Aug,39(2 Pt 2):372-4.
View this publication in the PUBMED databaseDifferential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Blood. 1998 Jun 1,91(11):4273-81.
View this publication in the PUBMED databaseFunctional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R. Br J Haematol. 1998 Sep,102(4):1069-80.
View this publication in the PUBMED databaseOn the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R, Egle A, Villunger A. Leuk Lymphoma. 1998 Nov,31(5-6):477-90.
View this publication in the PUBMED databaseSynergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.
Villunger A, Ghaffari-Tabrizi N, Tinhofer I, KrumbГ¶ck N, Bauer B, Schneider T, Kasibhatla S, Greil R, Baier-Bitterlich G, Uberall F, Green DR, Baier G. Eur J Immunol. 1999 Nov,29(11):3549-61.
View this publication in the PUBMED databaseComparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G, Holzner B, Kopp M, DГјnser M, Margreiter R, Greil R, Sperner-Unterweger B. J Clin Oncol. 1999 Sep,17(9):2932-40.
View this publication in the PUBMED databaseExpression of Apo-1/Fas (CD95), Bcl-2 Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, GrГјnewald K, Greil R. Br J Haematol. 1997 May,97(2):418-28.
View this publication in the PUBMED database